Shixuan Peng | Oncology | Excellence in Research Award

Published on by Young Scientists Awards

Ms. Shixuan Peng | Oncology | Excellence in Research Award

 Peking University, China

Shixuan Peng is an emerging clinical researcher and medical scholar specializing in anesthesiology and oncology. With a foundational background in clinical medicine and growing expertise in cancer-related translational research, Peng has contributed extensively to peer-reviewed publications, particularly in oncology, critical care, and molecular medicine. He is known for his analytical skills in handling large clinical datasets and his strong command of scientific writing. As a first and corresponding author on numerous high-impact papers, Peng has explored diverse research topics such as DNA methylation in female tumors, mortality predictors in critical care, and immunotherapy mechanisms. Actively engaged in collaborative studies with renowned institutions, he integrates basic science with clinical outcomes, aiming to improve precision diagnostics and treatment strategies. Alongside his academic pursuits, he has reviewed for multiple international journals and mentored by respected faculty, affirming his growing impact in the scientific community.

Profile

Scopus

Scholar

🎓 Education

Shixuan Peng pursued his undergraduate degree in Anesthesiology at the University of South China from 2017 to 2022, where he developed a solid clinical foundation and early exposure to research in perioperative care. Currently, he is completing his Master’s in Oncology at the same university (2022–2025), where his academic focus has transitioned toward cancer biology, clinical trials, and evidence-based treatment strategies. During his postgraduate studies, Peng engaged in extensive laboratory work and advanced statistical modeling for clinical outcomes research. He has also honed his skills in molecular techniques such as PCR, western blotting, and flow cytometry, guided by prominent mentors at Central South University’s Xiangya Hospital. His formal education is further enriched by hands-on experience in bioinformatics and the analysis of critical care databases like MIMIC-III and MIMIC-IV. His academic training has been tailored to bridge the gap between translational research and clinical application, with an emphasis on cancer immunology and molecular oncology.

💼 Experience

Shixuan Peng has diverse academic and clinical research experience, serving as a research assistant under Professors Hong Liu and Xingli Zhang at Xiangya Hospital, Central South University, where he investigates the NUDT21 gene’s role in pyroptosis. Since 2023, he has worked on multiple high-impact studies analyzing clinical outcomes using real-world data from ICU settings, exploring relationships between serum markers and mortality in heart failure and sepsis patients. His practical skills include clinical data analysis, molecular biology techniques, and the creation of scientific visuals. Peng’s expertise in academic writing and interpretation of large-scale datasets has positioned him as a reliable collaborator in multi-author projects. His roles have spanned project design, data cleaning, statistical analysis, and manuscript drafting. Beyond his research assistantship, Peng frequently collaborates with oncology and cardiology units, providing multidisciplinary insight. His expanding responsibilities in project management and scientific communication demonstrate his readiness for independent research leadership in clinical and translational medicine.

🏆 Awards and Honors

Although early in his academic career, Shixuan Peng has distinguished himself through scholarly excellence, becoming first or corresponding author on more than a dozen indexed journal publications in high-impact venues such as Biochim Biophys Acta, International Journal of Surgery, and Cancer Immunology, Immunotherapy. His recognition as a peer reviewer for respected journals including Frontiers in Immunology, BMC Anesthesiology, and Medicine reflects his growing authority in the field. He was selected for data mentorship programs and collaborative research under prestigious faculty at Xiangya Hospital, which signifies academic trust in his abilities. While not formally listed with national awards yet, his consistent publication in Q1/Q2 journals and co-leadership on systematic reviews and meta-analyses represent critical accomplishments. His ongoing involvement in cutting-edge cancer immunotherapy projects and predictive modeling in cardiovascular diseases positions him for future accolades in precision medicine and clinical epidemiology. His rapid progression underscores his potential for future academic and research awards.

🔬 Research Focus

Shixuan Peng’s research focuses on oncology, critical care outcomes, and translational medicine, with a strong emphasis on clinical epidemiology and molecular diagnostics. He has contributed significantly to understanding the prognostic value of biomarkers such as serum sodium, red blood cell distribution width, and serum anion gap in ICU patients. In oncology, his interests lie in tumor immunotherapy, cancer-related pain management, and DNA methylation testing in gynecologic tumors. Peng also investigates treatment response predictors in KRAS-mutated lung cancer and hepatocellular carcinoma, often using retrospective analyses of large clinical datasets like MIMIC-III and IV. He is engaged in studies exploring the integration of immune checkpoint inhibitors into multimodal strategies for liver cancer. His work blends clinical informatics with lab-based insights, including the role of genes like NUDT21 in cell death mechanisms. With experience in scientific visualization and academic writing, his research aims to translate lab findings into meaningful clinical applications.

 Conclusion

Shixuan Peng is a highly capable and driven early-career researcher whose contributions to oncology and clinical science are both substantial and timely. His publishing record, technical skill set, and interdisciplinary focus position him as a deserving candidate for the Excellence in Research Award. With continued development in research leadership and clinical integration, he is poised to make sustained, high-impact contributions to the medical research community.

Publication

  • Bifidobacterium modulation of tumor immunotherapy and its mechanism | 2024 | B Pei, S Peng, C Huang, F Zhou | Cancer Immunology, Immunotherapy 73(5), 94

  • Relationship between serum sodium levels and all-cause mortality in congestive heart failure patients: a retrospective cohort study based on the MIMIC-III database | 2023 | S Peng, J Peng, L Yang, W Ke | Frontiers in Cardiovascular Medicine 9, 1082845

  • Association between red blood cell distribution width and all-cause mortality in unselected critically ill patients: Analysis of the MIMIC-III database | 2023 | S Peng, W Li, W Ke | Frontiers in Medicine 10, 1152058

  • The association between serum anion gap and all‐cause mortality of unselected adult patients: A retrospective cohort study of >20,000 patients | 2023 | X Ji, S Peng | Journal of Clinical Laboratory Analysis 37(1), e24818

  • The relationship between preoperative anemia and length of hospital stay among patients undergoing radical surgery for esophageal carcinoma: a single-centre retrospective study | 2023 | Z Zheng, S Peng, J Yang, W Ke | BMC Anesthesiology 23(1), 322

  • Potential applications of DNA methylation testing technology in female tumors and screening methods | 2023 | S Peng, X Zhang, Y Wu | Biochimica et Biophysica Acta (BBA) – Reviews on Cancer 1878(5), 188941

  • The application and therapeutic effect of botulinum toxin type A (BTX-A) in the treatment of patients with pain after cancer treatment: a systematic review and meta-analysis | 2024 | S Li, S Peng, F Chen, B Zeng, Z Zhang, Z Zhang | International Journal of Surgery 110(2), 1215–1223

  • Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics | 2023 | Y Zhang, F Zeng, S Peng, Y Chen, W Jiang, Z Wang, L Deng, Z Huang, … | Expert Review of Respiratory Medicine 17(9), 743–751

  • The relationship between serum anion gap levels and short-, medium-, and long-term all-cause mortality in ICU patients with congestive heart failure: a retrospective cohort study | 2024 | S Peng, Q Chen, W Ke, Y Wu | Acta Cardiologica 79(6), 705–719

  • Predicting In-Hospital Mortality in Myocardial Infarction: A Nomogram-Based Retrospective Analysis of the MIMIC-IV Database | 2025 | S Peng, Q Chen, W Ke, Y Wu | Vascular Health and Risk Management, 461–476

  • Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges | 2025 | B Pei, S Peng, W Chen, L Lai, F Zhou | Technology in Cancer Research & Treatment 24, 15330338251334209

  • Perspectives on cancer therapy—synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges | 2025 | S Peng, M Long, Q Chen, Z Yin, C Zeng, W Zhang, Q Wen, X Zhang, W Ke, … | Cell Death Discovery 11(1), 179

  • Mendelian randomization analyses support causal relationships between HPV infection and colorectal cancer | 2024 | B Pei, P Liu, S Peng, F Zhou | Discover Oncology 15(1), 795

  • Renewed call for action: Highlight negative results to improve science | 2024 | B Pei, H Yang, S Peng | Clinics 79, 100426

  • ICIs in hepatocellular carcinoma: A comprehensive analysis of path forward for multimodal treatment strategies | 2024 | S Peng, Q Chen, Y Wu | Hepatology Communications 8(8), e0509

 

Rumeysa Çolak | Oncologyst | Best Researcher Award

Published on by Young Scientists Awards

Dr. Rumeysa Çolak | Oncologyst | Best Researcher Award

Bakırköy Dr.Sadi Konuk Training and Research Hospital ,Turkey 🏆

Dr. Rumeysa Çolak is a dedicated Research Assistant at the Department of Medical Oncology, Training and Research Hospital in Istanbul, Turkey, she graduated from Inonu University Faculty of Medicine in July 2015. Passionate about medical research, Dr. Çolak’s professional interests focus on oncology, internal medicine, and the clinical application of various treatments. She is proficient in English and contributes to the medical community through case presentations, research articles, and poster presentations. Dr. Çolak has participated in multiple scientific events, particularly focusing on novel cancer treatments and the intersection between chronic diseases like diabetes and inflammatory bowel diseases. Her commitment to improving patient outcomes in complex cases has earned her respect in the field.

Profile

Scopus

Education 🎓

Dr. Rumeysa Çolak graduated from the Faculty of Medicine at Inonu University in July 2015, with a strong foundation in medical science. Her dedication to advancing her knowledge and skills led her to further her education, earning her a role as a Research Assistant in 2022 at the Training and Research Hospital’s Medical Oncology Department. Alongside her medical degree, Dr. Çolak achieved a proficiency score of 65 on the YDS (Foreign Language Exam) in 2014, showcasing her ability to work in both Turkish and English-speaking environments. Her focus on oncology and medical research reflects her academic drive and desire to contribute to advancing healthcare in Turkey. Dr. Çolak’s comprehensive training in medical research, patient care, and specialized oncology practices supports her role as a valuable asset to the medical community.

Experience 🏢

Dr. Rumeysa Çolak’s professional journey began with her graduation from Inonu University Faculty of Medicine in 2015. Following her medical degree, she gained experience working in various clinical settings before securing her current position as a Research Assistant in the Medical Oncology Department at a renowned Training and Research Hospital in Istanbul. Since joining in 2022, Dr. Çolak has actively contributed to oncology research and patient care, particularly focusing on treatments for complex conditions such as advanced melanoma and metabolic diseases. She has been involved in scientific events, including case presentations and research articles, further solidifying her role in the medical community. Dr. Çolak’s expertise spans clinical research, patient management, and treatment protocols, with an emphasis on improving patient outcomes in challenging cases, such as liver failure with encephalopathy and inflammatory bowel diseases.

Research Interests 🔬

Dr. Rumeysa Çolak’s research focuses on advancing knowledge in oncology, particularly in the treatment of advanced melanoma and other complex diseases. Her work investigates innovative therapies such as nivolumab in patients with BRAF mutant advanced melanoma. In addition to her focus on oncology, Dr. Çolak’s research spans areas like inflammatory bowel diseases (IBD), examining the prevalence of irritable bowel syndrome-like symptoms in patients with inactive IBD and their impact on quality of life. She is also interested in diabetes and its comorbidities, having researched the use of statins in Type 2 diabetes patients. Through her research, Dr. Çolak aims to contribute to understanding the molecular mechanisms of diseases, the impact of treatments on patient outcomes, and ways to improve quality of life for patients with chronic conditions. Her ongoing work holds promise for the development of new strategies for managing complex medical conditions.

Awards 🏅

Dr. Rumeysa Çolak has been recognized for her dedication and contributions to medical research and clinical practice. Throughout her academic and professional journey, she has participated in several prestigious scientific events and conferences. One notable achievement includes her involvement in the 55th National Diabetes Metabolism and Nutritional Diseases Congress in Cyprus, where she presented a poster on statin use in Type 2 diabetes mellitus patients. Additionally, Dr. Çolak’s research articles and case presentations have garnered attention in the medical community, contributing to the understanding of complex conditions like irritable bowel syndrome and melanoma treatment. While she has not yet received specific awards, Dr. Çolak’s commitment to advancing healthcare and her proactive involvement in scientific research position her as a rising star in the field of oncology and internal medicine.

Publications 📚

1. Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy

2. ‘Statin Use and Objectives of The Target in Type 2 Diabetes Mellitus Patients: Is The Resistant in The Patient or The Physician?’

3. ‘Mutation in Complement Regulating Genes in Patients With Thrombotic Microangiopathic Resistant to Plasmapheresis Treatment’

4. ‘Assessment of Disease Activity by Fecal Occult Blood Test in Inflammatory Bowel Disease’

5. ‘Prevalence of Irritable Bowel Syndrome Like Symptoms in Patients With Inactive Inflammatory Bowel Disease and Relation With Quality of Life’

6. ‘A Case of Aggressive Prolactinoma’s Masked by HOOK Effect in Postmenopausal Period’

7. ‘Liver Transplantation Data of 20 Years Experience of Dokuz Eylul University Faculty of Medicine’

8. ‘Rare Gastric Metastasis of Breast Cancer’

Conclusion 🏅

Dr. Rumeysa Çolak is an excellent candidate for the “Best Researcher Award” given her diverse research portfolio, proven expertise, and significant impact in her field. She has demonstrated remarkable dedication to advancing both scientific knowledge and practical applications in oncology and chronic disease management. Her ongoing contributions to medical research and her ability to address complex health issues through innovative approaches underscore her suitability for such a prestigious recognition. Therefore, Dr. Çolak’s work makes her a strong contender for this award, and she deserves recognition for her excellence in research.